Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2459/JCM.0000000000000265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research Progress on Quantum Dot-Embedded Polymer Films and Plates for LCD Backlight Display.
Polymers (Basel)
January 2025
College of Engineering and Applied Sciences, Nanjing University, Nanjing 210023, China.
Quantum dot-polymer composites have the advantages of high luminescent quantum yield (PLQY), narrow emission half-peak full width (FWHM), and tunable emission spectra, and have broad application prospects in display and lighting fields. Research on quantum dots embedded in polymer films and plates has made great progress in both synthesis technology and optical properties. However, due to the shortcomings of quantum dots, such as cadmium selenide (CdSe), indium phosphide (InP), lead halide perovskite (LHP), poor water, oxygen, and light stability, and incapacity for large-scale synthesis, their practical application is still restricted.
View Article and Find Full Text PDFA Refined Nomenclature System to Better Discriminate Endo- and Exo-Type Fructanases and Glucanases.
Biomolecules
December 2024
Laboratory of Molecular Plant Biology and KU Leuven Plant Institute, Kasteelpark Arenberg 31, 3001 Leuven, Belgium.
Distinguishing between endo- and exo-type enzymes within the glycoside hydrolase (GH) classification presents significant challenges. Traditional methods, often based on endpoint activity measurements, do not capture the full range of products generated, leading to inconsistencies in classification. Not all exo-acting fructanases and glucanases produce monosaccharides (like fructose or glucose), while endo-acting enzymes do not solely produce higher-degree polymerization oligosaccharides.
View Article and Find Full Text PDFBeneficial Effects of FEC on an In-Situ Polymerized Deep Eutectic Electrolyte for Solid-State Batteries.
ACS Appl Mater Interfaces
January 2025
Institute of New Energy Material Chemistry, School of Materials Science and Engineering, Nankai University, Tianjin 300350, China.
Eutectic-based polymer electrolytes have emerged as promising solid electrolytes because of their ionic liquid-like properties, while modifications are essential to further increase their ionic conductivity at room temperature and solve their compatibility with lithium anode. In this work, an in situ polymerized composite electrolyte is modified by the addition of fluoroethylene carbonate (FEC) whose beneficial effect is systematically investigated in different contents. Poly(ethylene glycol) diacrylate (PEGDA), deep eutectic solvent (LiTFSI:-methylacetamide = 1:3), and alumina fiber work as the monomer, solvent, and three-dimensional skeleton, respectively.
View Article and Find Full Text PDFAccuracy of GFAP and UCH-L1 in predicting brain abnormalities on CT scans after mild traumatic brain injury: a systematic review and meta-analysis.
Eur J Trauma Emerg Surg
January 2025
Department of Neuroradiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Purpose: Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. In recent years, blood biomarkers including glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) have shown a promising ability to detect head CT abnormalities following TBI. This review aims to combine the existing research on GFAP and UCH-L1 biomarkers and examine how well they can predict abnormal CT results after mild TBI.
View Article and Find Full Text PDFBiodegradable polymeric microsphere formulations of full-length anti-VEGF antibody bevacizumab for sustained intraocular delivery.
Drug Deliv Transl Res
January 2025
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA.
Age-related macular degeneration (AMD) is one of the leading causes of central vision loss in the elderly population. Bevacizumab, a full-length humanized monoclonal anti-VEGF antibody, is commonly used off-label drug to treat AMD. However, the dosing regimen of bevacizumab and other anti-VEGF antibodies requires monthly intravitreal injections followed by regular intravitreal injections at 4-16-week intervals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!